Canaccord Genuity reiterates a 'Buy' on Momenta Pharmaceuticals (MNTA); Buy on weakness: Teva's Enox Minor Deficiency Letter, Six-Month Delay, No Fundamental Change
Tweet Send to a Friend
Canaccord Genuity reiterates a 'Buy' on Momenta Pharmaceuticals (NASDAQ: MNTA), PT $27.
Canaccord analyst says, "We think m-enoxaparin’s (MNTA/Sandoz generic ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Canaccord analyst says, "We think m-enoxaparin’s (MNTA/Sandoz generic ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
